

CLINICAL RESEARCH HIGHLIGHTS - IMMUNITY BOOSTER

A clinical case study on ACT 12 & ACT 13 in 100 mild to moderate COVID-19 subjects
In a clinical evaluation conducted over approximately **5 DAYS**,
the reported outcomes included:

CLINICAL PARAMETER		REPORTED OUTCOME	
	Faster RT-PCR Negativity (Average up to Day 5)	↑ >90%	Increase
	Fever (Reduction in average days)	↓ >90%	Reduced
	Loss of Taste & Smell (Relief in average days)	↓ >90%	Reduced
	Headache (Relief in average days)	↓ >90%	Reduced
	Body Ache (Relief in average days)	↓ >90%	Reduced
	Shortness of Breath (Relief in average days)	↓ >90%	Reduced
	SpO₂ Levels (Improvement in average days)	↑ >90%	Improvement
	CRP Levels (Reduction in average days up to Day 5)	↓ >90%	Reduced



These findings suggest that the **PHYTOCONSTITUENTS BASED IMMUNITY BOOSTER FORMULA (ACT 12 & ACT 13)** may be effective in **FASTER RECOVERY, IMPROVING SYMPTOMS, REDUCING INFLAMMATION,** and **ENHANCING IMMUNITY** safely over 5 days.



Reference-

1. https://wjpr.s3.ap-south-1.amazonaws.com/article_issue/1606545007.pdf